Form 4: Syndax CEO Sells Shares for Tax Obligations

Syndax Pharmaceuticals CEO Michael A. Metzger sold 17,159 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Michael A. Metzger, the Chief Executive Officer and a Director of Syndax Pharmaceuticals Inc (SNDX), reported a transaction involving the company's common stock.
• On February 9, 2026, Mr. Metzger disposed of 17,159 shares of common stock at a price of $21.028 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Mr. Metzger beneficially owns 491,690 shares of Syndax Pharmaceuticals common stock.
• The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine, non-discretionary transaction for tax purposes, which typically has a neutral impact on market sentiment and does not reflect a change in management's outlook.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it reports a past insider transaction.

Management Comments

• The sale represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions, where executives sell shares to satisfy tax obligations upon the vesting of equity awards, are a common and routine occurrence across all industries, particularly in the biotechnology and pharmaceutical sectors where equity compensation is prevalent. Such transactions are generally not indicative of a change in management's confidence or the company's operational performance.

Comparison to Industry Standards

• This type of transaction, a 'sell-to-cover' for tax withholding on vested restricted stock units, is standard practice for executives across publicly traded companies globally.
• Companies like Pfizer, Merck, and Johnson & Johnson frequently see similar Form 4 filings from their executives when equity awards vest, as it's a common mechanism to manage tax liabilities without requiring personal cash outlays.
• The execution under a Rule 10b5-1 plan further aligns this transaction with best practices for insider trading compliance, demonstrating a pre-planned, non-discretionary sale.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary sale for tax purposes and does not signal a change in management's confidence.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This transaction is a standard 'sell-to-cover' to meet tax obligations on vested restricted stock units, executed under a Rule 10b5-1 plan. It does not reflect a discretionary sale by the CEO or a change in his confidence in the company's prospects, thus maintaining a neutral stance on the stock is appropriate.

Keywords

Syndax Pharmaceuticals, SNDX, Michael A. Metzger, Insider Transaction, Form 4, Stock Sale, CEO, Restricted Stock Units, Tax Withholding, 10b5-1 Plan